よむ、つかう、まなぶ。
資料３－11―① 押谷先生・鈴木先生・西浦先生・脇田先生提出資料 (15 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431_00395.html |
| 出典情報 | 新型コロナウイルス感染症対策アドバイザリーボード (第110回 12／14)《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
30.
Lopez-Leon, S. et al. More than 50 long-term effects of COVID-19: a systematic
review and meta-analysis. Sci Rep 11, (2021).
31.
Antonelli, M., Pujol, J. C., Spector, T. D., Ourselin, S. & Steves, C. J. Risk of long
COVID associated with delta versus omicron variants of SARS-CoV-2. The Lancet 399,
2263–2264 (2022).
32.
Townsend, L. et al. Persistent poor health after covid-19 is not associated with
respiratory complications or initial disease severity. Ann Am Thorac Soc 18, 997–1003
(2021).
33.
Borch, L., Holm, M., Knudsen, M., Ellermann-Eriksen, S. & Hagstroem, S. Long
COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide
cohort study. Eur J Pediatr 181, 1597–1607 (2022).
34.
Woolf, S. H., Chapman, D. A., Sabo, R. T. & Zimmerman, E. B. Excess Deaths from
COVID-19 and Other Causes in the US, March 1, 2020, to January 2, 2021. JAMA -
Journal of the American Medical Association 325, 1786–1789 (2021).
35.
Islam, N. et al. Excess deaths associated with covid-19 pandemic in 2020: Age and sex
disaggregated time series analysis in 29 high income countries. The BMJ 373, (2021).
36.
NHS
backlog
data
analysis.
https://www.bma.org.uk/advice-and-support/nhs-
delivery-and-workforce/pressures/nhs-backlog-data-analysis.
37.
Mahase, E. Covid-19: Hospital and ambulance services struggle with huge demand and
staff illness. BMJ 377, o950 (2022).
38.
UK SAGE SPI-M-O. S Consensus statement on COVID-19, 26 January 2022 GOV.UK.
https://www.gov.uk/government/publications/spi-m-o-consensus-statement-oncovid-19-26-january-2022/spi-m-o-consensus-statement-on-covid-19-26-january2022.
39.
Li, R., Metcalf, C. J. E., Stenseth, N. C. & Bjørnstad, O. N. A general model for the
demographic signatures of the transition from pandemic emergence to endemicity. Sci
Adv 7, 9040–9051 (2021).
40.
Wang, Q. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and
XBB subvariants. bioRxiv 2022.11.23.517532 (2022) doi:10.1101/2022.11.23.517532.
41.
Twohig, K. A. et al. Hospital admission and emergency care attendance risk for SARSCoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort
study. Lancet Infect Dis 22, 35–42 (2022).
42.
Lustig, G. et al. SARS-CoV-2 evolves increased infection elicited cell death and fusion
in an immunosuppressed individual.
medRxiv 2022.11.23.22282673 (2022)
doi:10.1101/2022.11.23.22282673.
15
Lopez-Leon, S. et al. More than 50 long-term effects of COVID-19: a systematic
review and meta-analysis. Sci Rep 11, (2021).
31.
Antonelli, M., Pujol, J. C., Spector, T. D., Ourselin, S. & Steves, C. J. Risk of long
COVID associated with delta versus omicron variants of SARS-CoV-2. The Lancet 399,
2263–2264 (2022).
32.
Townsend, L. et al. Persistent poor health after covid-19 is not associated with
respiratory complications or initial disease severity. Ann Am Thorac Soc 18, 997–1003
(2021).
33.
Borch, L., Holm, M., Knudsen, M., Ellermann-Eriksen, S. & Hagstroem, S. Long
COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide
cohort study. Eur J Pediatr 181, 1597–1607 (2022).
34.
Woolf, S. H., Chapman, D. A., Sabo, R. T. & Zimmerman, E. B. Excess Deaths from
COVID-19 and Other Causes in the US, March 1, 2020, to January 2, 2021. JAMA -
Journal of the American Medical Association 325, 1786–1789 (2021).
35.
Islam, N. et al. Excess deaths associated with covid-19 pandemic in 2020: Age and sex
disaggregated time series analysis in 29 high income countries. The BMJ 373, (2021).
36.
NHS
backlog
data
analysis.
https://www.bma.org.uk/advice-and-support/nhs-
delivery-and-workforce/pressures/nhs-backlog-data-analysis.
37.
Mahase, E. Covid-19: Hospital and ambulance services struggle with huge demand and
staff illness. BMJ 377, o950 (2022).
38.
UK SAGE SPI-M-O. S Consensus statement on COVID-19, 26 January 2022 GOV.UK.
https://www.gov.uk/government/publications/spi-m-o-consensus-statement-oncovid-19-26-january-2022/spi-m-o-consensus-statement-on-covid-19-26-january2022.
39.
Li, R., Metcalf, C. J. E., Stenseth, N. C. & Bjørnstad, O. N. A general model for the
demographic signatures of the transition from pandemic emergence to endemicity. Sci
Adv 7, 9040–9051 (2021).
40.
Wang, Q. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and
XBB subvariants. bioRxiv 2022.11.23.517532 (2022) doi:10.1101/2022.11.23.517532.
41.
Twohig, K. A. et al. Hospital admission and emergency care attendance risk for SARSCoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort
study. Lancet Infect Dis 22, 35–42 (2022).
42.
Lustig, G. et al. SARS-CoV-2 evolves increased infection elicited cell death and fusion
in an immunosuppressed individual.
medRxiv 2022.11.23.22282673 (2022)
doi:10.1101/2022.11.23.22282673.
15